Understanding immunotherapy and its management
<p>A few tumours are exceptionally stubborn to oral chemotherapy. The endurance of tumours in a few cases is helped by checkpoint immunomodulation to keep up the unevenness between resistant reconnaissance and disease cell division. Checkpoint counteracting agent inhibitors, for example, again...
Guardat en:
Autors principals: | Nadiminti Rajesh Kumar (Autor), Sajid Alvi (Autor) |
---|---|
Format: | Llibre |
Publicat: |
International Journal of Immunotherapy and Cancer Research - Peertechz Publications,
2021-01-12.
|
Matèries: | |
Accés en línia: | Connect to this object online. |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Ítems similars
Ítems similars
-
Immunotherapy and its advances in the management of head-and-neck cancer
per: Sajad Ahmad Buch, et al.
Publicat: (2019) -
Nanotechnology for boosting ovarian cancer immunotherapy
per: Prabhjot Kaur, et al.
Publicat: (2024) -
Cancer immunotherapy and its facilitation by nanomedicine
per: Chao Sui, et al.
Publicat: (2024) -
Adverse Events of Oncologic Immunotherapy and Their Management
per: Fedricker Diane Barber
Publicat: (2019) -
CANCER IMMUNOLOGY AND IMMUNOTHERAPY - UNDERSTANDING AND ADAPTATION THE CURRENT EVIDENCE TO OPTIMIZE PATIENT THERAPY OUTCOMES.
per: Orlin Savov, et al.
Publicat: (2015)